09-11-2015, 01:04 PM
Quote:It’s Friday. And according to the latest data for Gilead Sciences (GILD), hepatitis-C prescriptions continued to slow last week.
According to IMS, Harvoni prescriptions total fell 2% from the previous week to 7,333 during the week ended Sept. 4, while new prescriptions fell 3% to 2,672. Combined with Sovaldi, total hepatitis-C prescriptions fell 2% to 9,015, while new prescriptions declined 1% to 3,79.
RBC analyst Michael Yee estimates that U.S. hepatitis-C sales should come in at around $12.2 billion in 2015, just below the consensus for $12.7 billion.
From Barron's web site.
Not changing my theory and Ari's comments linked by Rapidacid just reinforced my thoughts.